H.C. Wainwright Lifts CRISPR Therapeutics’ (CRSP) Price Target on CASGEVy Sales Growth
CRISPR Therapeutics AG (NASDAQ:CRSP) in Cathie Wood's Stock Portfolio is one of the top 10 stocks to buy now. On August 7, analysts at H.C.
Crispr Therapeutics Ag (CRSP)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 10,182,590 | $495,281,183 | +1% | 3.63% |
| 2. | Orbis Investment Management William B. Gray | 2,764,532 | $134,466,837 | +77% | 0.65% |
| 3. | EcoR1 Capital Oleg Nodelman | 1,389,276 | $67,574,385 | 4% | |
| 4. | Two Sigma Advisors John Overdeck And David Siegel | 1,344,700 | $65,406,208 | +69% | 0.13% |
| 5. | SR One Capital Simeon George | 1,048,951 | $51,020,977 | 11.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $57.03 | 20,000 | $1,140,600.00 | 22,000 | 2025-08-06 | Filing | |
| $52.03 | 960,983 | $49,999,945.49 | 1,730,179 | 2025-07-16 | Filing | |
| $52.03 | 22,319 | $1,161,257.57 | 238,897 | 2025-07-16 | Filing | |
| $52.03 | 6,510 | $338,715.30 | 69,687 | 2025-07-16 | Filing | |
| $44.85 | 7,000 | $313,947.90 | 7,000 | 2025-02-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $58.15 | 13,081 | $760,660.15 | 207,004 | 2025-08-18 | Filing | |
| $35.94 | 3,932 | $141,316.08 | 6,068 | 2025-05-29 | Filing | |
| $41.23 | 10,031 | $413,578.13 | 195,085 | 2025-03-21 | Filing | |
| $41.23 | 1,714 | $70,668.22 | 10,544 | 2025-03-21 | Filing | |
| $41.23 | 2,197 | $90,582.31 | 16,767 | 2025-03-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,066,358 | $295,067,652 | 0.01% | |
| 2. | 5,593,747 | $272,079,854 | 0.05% | |
| 3. | 3,270,596 | $159,081,789 | 0.01% | |
| 4. | 2,843,577 | $138,311,585 | 0.02% | |
| 5. | 2,414,838 | $117,457,720 | 0.07% |
News See All
Cathie Wood Stock Portfolio: Top 10 Stocks to Buy Now
Cathie Wood, the CEO and chief investment officer of ARK Investment Management, has established a reputation thanks to high-conviction bets that often yield significant returns.
What Makes Crispr Therapeutics Ag (CRSP) a Good Buy?
RGA Investment Advisors, an investment management company, has released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Jim Cramer Weighed in on These 17 Stocks
“Sometimes you just can't pin a market down. You see things that are so solid, real companies doing real things and getting rewarded for them.
CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading
CRISPR Therapeutics soared by 18.22 percent on Friday to close at $65.13 apiece to hit a new all-time high as investors took path from a recent insider trading that gobbled up shares worth more than $...
CRISPR Therapeutics (CRSP) Jumps 9.6% on Biotech Rally
Additionally, investors may have begun repositioning portfolios ahead of the release of second-quarter earnings results.
H.C. Wainwright Reaffirms Buy Rating on CRISPR Therapeutics After CTX310 Update
CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best CRISPR stocks to buy. Following CRISPR Therapeutics AG (NASDAQ:CRSP)’s supplemental update to its Phase 1 CTX310 trial findings, H.C.
Top 10 CRISPR Stocks to Buy Now
Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address unresolved medical needs.
CRISPR Therapeutics AG (CRSP): A Bull Case Theory
We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on Two Natural Cap’s Substack. In this article, we will summarize the bulls’ thesis on CRSP.
12 Most Promising Biotech Stocks According to Wall Street Analysts
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
Billionaire Hedge Funds
